APH.TO - Aphria Inc.

Toronto - Toronto Delayed Price. Currency in CAD
11.00
-0.14 (-1.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.14
Open11.19
Bid10.95 x 0
Ask11.10 x 0
Day's Range10.77 - 11.20
52 Week Range4.55 - 24.75
Volume2,639,826
Avg. Volume4,783,256
Market Cap2.303B
Beta4.36
PE Ratio (TTM)52.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire2 days ago

    Scythian Announces ABP S.A.’s First Purchase Order with Aphria Inc.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company that Scythian is in the process of acquiring, has received its first purchase order  (the “Order”) of CBD oil, which is to be fulfilled under the supply agreement with Aphria Inc. (APH.TO) (“Aphria”), a prominent Canadian producer of medical cannabis. The Order is for Aphria’s renowned CBD oil strain, Rideau.

  • CNW Group3 days ago

    Aphria Launches Solei, its First Adult-Use Brand, Designed for the Modern Cannabis Consumer

    LEAMINGTON, ON, April 17, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today introduced its first brand designed for Canada's new adult-use market, Solei Sungrown Cannabis ("Solei"). Solei has been designed to demystify cannabis and will enable current and novice users alike to control and enrich their cannabis journey, pairing an assortment of carefully curated products and strains with different experiences. Solei was created specifically for what will be one of the largest segments in the Canadian cannabis landscape, defined not by age, gender or geography, but rather by a shared mindset and attitude.

  • CNW Group4 days ago

    Aphria Inc. - Revenue Growth and Sub $1.00 Cash Cost per Gram Metric Highlight Quarter

    Tenth consecutive quarter of positive adjusted EBITDA 2 Significant levels of cash available for deployment in attractive investment opportunities LEAMINGTON, ON , April 16, 2018 /CNW/ - Aphria Inc. (" ...

  • CNW Group10 days ago

    Aphria to Announce Third Quarter Results on April 16, 2018

    LEAMINGTON, ON, April 10, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) will release its third quarter results for 2018 on April 16, 2018. Financial results are expected to be released at approximately 7:00am ET, through SEDAR and on Aphria's website at www.aphria.ca/investors. A conference call is scheduled for 9:00am ET and will feature a presentation by Aphria executives followed by a question and answer period with analysts.

  • ACCESSWIRE11 days ago

    Today’s Research Reports on Aphria, Titan Medical, ProMIS Neurosciences and Cardiome Pharma

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group15 days ago

    Aphria provides update on Part III expansion operations

    "We're incredibly excited and proud of our whole team that has ramped up operations in our state-of-the-art Part III greenhouse expansion with incredible speed and care," said Vic Neufeld, CEO of Aphria. "As we prepare to make our first harvest from Part III later this month, work continues to rapidly advance on our 700,000-square-foot Part IV expansion, which we anticipate will have its first sale early next year.

  • PR Newswire24 days ago

    Aphria launches Aphria International and provides updates on worldwide operations

    LEAMINGTON, ON, March 27, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) is pleased to provide the following updates to the Company's worldwide operations and activities. Nuuvera Inc. will be renamed Aphria International Inc. ("Aphria International") and remain a wholly-owned subsidiary of Aphria.

  • CNW Group24 days ago

    Aphria launches Aphria International and provides updates on worldwide operations

    LEAMINGTON, ON, March 27, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) is pleased to provide the following updates to the Company's worldwide operations and activities. Nuuvera Inc. will be renamed Aphria International Inc. ("Aphria International") and remain a wholly-owned subsidiary of Aphria.

  • CNW Group28 days ago

    Aphria and Nuuvera Announce Closing Of Arrangement

    LEAMINGTON and TORONTO, ON, March 23, 2018 /CNW/ - Aphria Inc. ("Aphria") (TSX:APH and US OTC: APHQF) and Nuuvera Inc. ("Nuuvera") (TSXV:NUU.V - News) are pleased to announce that they have completed the previously announced arrangement (the "Arrangement") under the provisions of the Business Corporations Act (Ontario), pursuant to which, among other things, Aphria has acquired all of the common shares of Nuuvera (the "Nuuvera Shares") not already owned by it. Under the terms of the Arrangement, each former Nuuvera shareholder is now entitled to receive $0.62 in cash, rather than $0.60, as previously announced, plus 0.3546 of a common share of Aphria, for each Nuuvera Share held prior to the Arrangement (the "Consideration").

  • PR Newswirelast month

    Aphria signs exclusive agreement with Argentina-based importer to supply medical cannabis in Argentina

    LEAMINGTON, ON, March 21, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has signed an exclusive supply agreement with an Argentinan based pharmaceutical import and distribution company, which is licensed to import, sell and distribute medical products and derivatives in Argentina. The importer is currently securing an import license for cannabis in Argentina. "We are excited to enter the Argentinian market through this initial supply agreement," said Vic Neufeld, CEO of Aphria. "We see tremendous potential for medical cannabis in several emerging markets in South America, including Argentina.

  • CNW Grouplast month

    Aphria signs exclusive agreement with Argentina-based importer to supply medical cannabis in Argentina

    LEAMINGTON, ON, March 21, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has signed an exclusive supply agreement with an Argentinan based pharmaceutical import and distribution company, which is licensed to import, sell and distribute medical products and derivatives in Argentina. The importer is currently securing an import license for cannabis in Argentina. "We are excited to enter the Argentinian market through this initial supply agreement," said Vic Neufeld, CEO of Aphria. "We see tremendous potential for medical cannabis in several emerging markets in South America, including Argentina.

  • CNW Grouplast month

    Nuuvera announces shareholder approval of plan of arrangement with Aphria Inc.

    LEAMINGTON, ON and TORONTO, March 20, 2018 /CNW/ - Nuuvera Inc. (the "Company" or "Nuuvera") (TSXV:NUU) and Aphria Inc. ("Aphria") (TSX: APH and US OTC: APHQF) are pleased to announce that, at the special meeting of shareholders of Nuuvera held today (the "Meeting"), the shareholders of Nuuvera overwhelmingly voted in favour of a special resolution to approve the proposed plan of arrangement with Aphria previously announced on January 29, 2018 (the "Arrangement") pursuant to which, among other things, Aphria will acquire all of the issued and outstanding shares of Nuuvera not already owned by it.

  • PR Newswirelast month

    Aphria receives third-party independent GMP certification of Leamington growing and processing facilities

    LEAMINGTON, ON, March 16, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced it has received third-party independent GMP certification of its Leamington, Ontario growing and processing facilities. Granted by internationally-renowned firm SGS, the certification is for the current Good Manufacturing Practice ("cGMP") standards of CFR 21 parts 210/211 established by the United States Food and Drug Administration ("USFDA") for Active Pharmaceutical Ingredients and Finished Pharmaceuticals.

  • CNW Grouplast month

    Aphria receives third-party independent GMP certification of Leamington growing and processing facilities

    Aphria is the first Canadian Licensed Producer to be certified by SGS to the USFDA standards for Active Pharmaceutical Ingredients and Finished Pharmaceuticals LEAMINGTON, ON , March 16, 2018 /CNW/ - Aphria ...

  • PR Newswirelast month

    Aphria's Australian-based partner Althea receives Medical Cannabis License for cultivation

    LEAMINGTON, ON, March 15, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that its Australian-based partner Althea Company Pty Ltd. ("Althea" or the "Australian Company") was granted a Medical Cannabis License (the "License") by the Australian Government's Office of Drug Control ("Office of Drug Control"). The License provides Althea with authorization to cultivate medical cannabis, enabling the Australian Company to begin immediate construction on a state-of-the art greenhouse facility in Victoria.

  • CNW Grouplast month

    Aphria's Australian-based partner Althea receives Medical Cannabis License for cultivation

    LEAMINGTON, ON, March 15, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that its Australian-based partner Althea Company Pty Ltd. ("Althea" or the "Australian Company") was granted a Medical Cannabis License (the "License") by the Australian Government's Office of Drug Control ("Office of Drug Control"). The License provides Althea with authorization to cultivate medical cannabis, enabling the Australian Company to begin immediate construction on a state-of-the art greenhouse facility in Victoria.

  • PR Newswirelast month

    Aphria More Than Triples Production Capacity with Health Canada Approval for Part III Expansion

    LEAMINGTON, ON, March 13, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced  that the Company received a license amendment from Health Canada that provides Aphria with additional production space of 200,000 square feet, as part of its Part III expansion at its facility in Leamington, Ontario. This will more than triple the Company's production capacity of medical cannabis from 9,000 kg annually to 30,000 kg annually.

  • CNW Grouplast month

    Aphria More Than Triples Production Capacity with Health Canada Approval for Part III Expansion

    LEAMINGTON, ON, March 13, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced  that the Company received a license amendment from Health Canada that provides Aphria with additional production space of 200,000 square feet, as part of its Part III expansion at its facility in Leamington, Ontario. This will more than triple the Company's production capacity of medical cannabis from 9,000 kg annually to 30,000 kg annually.

  • GlobeNewswirelast month

    Scythian Biosciences Announces 4-For-1 Stock Split and Appointment of Vic Neufeld as New Chairman of the Board of Directors

    TORONTO, March 12, 2018-- Scythian Biosciences Corp. announces that, further to its press release on March 9, 2018 whereby the Company announced shareholder approval of an up to eight for one stock split ...

  • Hiku Brands Applies for Cannabis Oil License, Launches Innovative Extraction Program in Partnership With Vitalis and Secures Prairies Expansion Rights for Tokyo Smoke Brand
    CNW Grouplast month

    Hiku Brands Applies for Cannabis Oil License, Launches Innovative Extraction Program in Partnership With Vitalis and Secures Prairies Expansion Rights for Tokyo Smoke Brand

    TORONTO, March 7, 2018 /CNW/ - Hiku Brands Company Ltd. ("Hiku" or the "Company") (CSE:HIKU), Canada's first vertically-integrated cannabis brand house, is pleased to provide an update of the Company's recent corporate development initiatives. Hiku's wholly-owned subsidiary DOJA Cannabis Ltd. ("DOJA"), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"), submitted its application to Health Canada for the production of medical cannabis oils at its second site facility (the "FUTURE LAB") located in Kelowna, British Columbia.

  • Hiku's Licensed Cannabis Producer Completes Pre-Sales Inspection and Accelerates Expansion Plans on the Back of Retail Cannabis Win in Manitoba
    CNW Group2 months ago

    Hiku's Licensed Cannabis Producer Completes Pre-Sales Inspection and Accelerates Expansion Plans on the Back of Retail Cannabis Win in Manitoba

    TORONTO, March 1, 2018 /CNW/ - Hiku Brands Company Ltd. ("Hiku" or the "Company") (CSE:HIKU), Canada's first vertically-integrated cannabis brand house, is pleased to announce its wholly-owned subsidiary DOJA Cannabis Ltd. ("DOJA"), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"), has completed Health Canada's ("HC") Pre-Sales License Inspection of DOJA's West Kelowna facility. Over a three-day period ending February 15, 2018, HC inspectors were onsite verifying information submitted by DOJA as part of its application and assessing compliance with the applicable sections of the ACMPR prior to license approval.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Aphria, Centric Health, Helix BioPharma and TearLab

    NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group2 months ago

    Aphria Amends Arrangement Agreement with Nuuvera

    LEAMINGTON, ON, Feb. 20, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) announces today that it has entered into an amending agreement (the "Amendment") to the previously announced arrangement agreement (the "Arrangement Agreement") dated January 28, 2018 between Aphria and Nuuvera Inc. ('Nuuvera") whereby the Company and Nuuvera have agreed to amend the Arrangement Agreement to reduce both the required level of unrestricted cash and the consideration payable to holders of Nuuvera's common shares (each a "Nuuvera Share"). The consideration under the Amendment has been reduced from $1.00 in cash plus 0.3546 of an Aphria common share (each an "Aphria Share") for each Nuuvera Share to $0.60 in cash plus 0.3546 of an Aphria Share for each Nuuvera Share.

  • PR Newswire2 months ago

    Aphria Amends Arrangement Agreement with Nuuvera

    LEAMINGTON, ON, Feb. 20, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) announces today that it has entered into an amending agreement (the "Amendment") to the previously announced arrangement agreement (the "Arrangement Agreement") dated January 28, 2018 between Aphria and Nuuvera Inc. ('Nuuvera") whereby the Company and Nuuvera have agreed to amend the Arrangement Agreement to reduce both the required level of unrestricted cash and the consideration payable to holders of Nuuvera's common shares (each a "Nuuvera Share"). The consideration under the Amendment has been reduced from $1.00 in cash plus 0.3546 of an Aphria common share (each an "Aphria Share") for each Nuuvera Share to $0.60 in cash plus 0.3546 of an Aphria Share for each Nuuvera Share.

  • CNW Group2 months ago

    Aphria signs letter of intent with SAQ to supply up to 12,000 kg of cannabis annually to Quebec market

    Aphria becomes one of the first suppliers of adult-use cannabis to La Belle Province LEAMINGTON, ON , Feb. 14, 2018 /CNW/ - Aphria Inc. (" Aphria " or the " Company ") ( TSX: APH and ...